3 June 2026
Click to read the Medicines Patent Pool (MPP)’s most recent brochure. The document explains how MPP works to increase access to treatments in low- and middle-income countries, and it also presents some key figures about MPP’s achievements from 2010 to date.
MPP’s 2026 Brochure
MPP’s 2026 Brochure (Chinese version)
The brochure explains how MPP uses public health-oriented voluntary licensing and technology transfer to enable the development, production and scale-up of quality-assured medicines and health technologies.
It provides an overview of:
The brochure also presents the scale and public health impact of MPP’s work. Selected results include:
Download the MPP 2026 brochure to learn more about MPP’s licensing model, partnerships, focus areas, digital tools and contribution to expanding equitable access to medicines and health technologies.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.